Brokerages predict that Sensus Healthcare Inc (NASDAQ:SRTS) will report $7.76 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Sensus Healthcare’s earnings, with estimates ranging from $7.15 million to $8.50 million. Sensus Healthcare posted sales of $5.96 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 30.2%. The business is expected to announce its next earnings results on Thursday, May 2nd.
On average, analysts expect that Sensus Healthcare will report full year sales of $34.60 million for the current year, with estimates ranging from $32.70 million to $35.80 million. For the next fiscal year, analysts anticipate that the business will report sales of $44.89 million, with estimates ranging from $43.00 million to $46.31 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, February 14th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Sensus Healthcare had a negative return on equity of 10.86% and a negative net margin of 7.65%. The business had revenue of $8.08 million during the quarter, compared to analysts’ expectations of $7.33 million.
In other news, EVP Richard Golin sold 5,943 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $7.56, for a total transaction of $44,929.08. Following the completion of the transaction, the executive vice president now directly owns 925,237 shares of the company’s stock, valued at approximately $6,994,791.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 7,203 shares of company stock valued at $54,379 over the last ninety days. Company insiders own 41.10% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $86,000. B. Riley Financial Inc. bought a new position in shares of Sensus Healthcare in the third quarter valued at $168,000. BlackRock Inc. grew its stake in shares of Sensus Healthcare by 10.2% in the fourth quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock valued at $192,000 after buying an additional 2,418 shares in the last quarter. Stonepine Capital Management LLC bought a new position in shares of Sensus Healthcare in the third quarter valued at $317,000. Finally, Geode Capital Management LLC grew its stake in shares of Sensus Healthcare by 222.5% in the fourth quarter. Geode Capital Management LLC now owns 45,034 shares of the company’s stock valued at $333,000 after buying an additional 31,070 shares in the last quarter. 6.57% of the stock is owned by institutional investors.
NASDAQ SRTS opened at $6.70 on Friday. Sensus Healthcare has a 52-week low of $5.00 and a 52-week high of $9.23. The company has a market cap of $108.60 million, a P/E ratio of -47.86 and a beta of -0.46.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Story: Trading Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.